AstraZeneca

AstraZeneca is a holding company. Through its subsidiaries, Co. operates as a biopharmaceutical company engaged in discovering, developing, manufacturing and commercializing its pipeline of small molecule and biologic prescription medicines, including targeted business development through collaboration, in-licensing and acquisitions. Co. is focused on three main therapy areas: Oncology, Cardiovascular and Metabolic Diseases, and Respiratory. Co. is also selectively active in autoimmunity, infection and neuroscience. In addition, Co. works across small molecules, oligonucleotides and other drug platforms, as well as biologic medicines.
  • TickerAZN
  • ISINGB0009895292
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Analysts

ASTRAZENECA PLC. sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of ASTRAZENECA PLC. (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date March 22, 2019, the closing price was GBp 6,351.00 and its potential was estimated at GBp 6,780.73.

Damien Conover

Morningstar | AZN Updated Forecasts and Estimates from 08 Mar 2019

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is finally offsetting the recent patent losses on gastrointestinal drug Nexium and cholesterol reducer Crestor that have weighed on the company's growth potential. Although AstraZeneca's pipeline ranks toward the middle of its peer group, we think the company is developing several key products that hold blockbuster potential. In particular, the company's recently launched cancer drugs Tagrisso and Imfinzi ar...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Martial Descoutures
  • Olfa Taamallah
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/26/2019

The acquisition of SABMiller has not delivered on its initial promises, due to the challenges of absorbing the debt quickly and a problematic geographic mix. However, the group still boasts growth potential which adjustments to its debt and asset arbitration could bring to light, particularly in the context of the shift in the ZBB (zero based budgeting) model. We simulate a partial divestment of the Asian assets and the buyout of 78% of the JVs with Castel in Africa. This would offer ...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Martial Descoutures
  • Olfa Taamallah
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 26/02/2019

Même si le rachat de SABMiller n’a pas répondu aux promesses initiales en raison d’un endettement difficile à résorber rapidement et d’un mix géographique contraignant, le groupe recèle encore un potentiel de croissance que le réaménagement de la dette et un arbitrage entre les actifs pourraient mettre en lumière, notamment dans le contexte de mutation du modèle ZBB (zero based budgeting). Aussi, nous simulons une cession partielle des actifs asiatiques et le rachat des 78% des JV ave...

Martial Descoutures ...
  • Pierre Corby

AstraZeneca : Feedback road show : Execution exceeds expectations

>Road show with CFO & Head of R&D Oncology: confidence restored - We accompanied Marc Dunoyer, CFO of Astrazeneca, and the new Head of R&D Oncology Jose Baselga (Executive VP R&D Oncology) on a road show in Paris after the publication of the FY 2018 results. It appears that, following doubts arising from recent managerial departures (drop in share price from 6,000p to 5,300p in January), the rapid reorganisation of R&D and especially the FY 2018 publication in mid-Feb...

AstraZeneca PLC: EBITDA growth to drive strengthening of credit metrics in 2019

Comment on AstraZeneca's full year 2018 results and outlook for 2019

AstraZeneca PLC: Although rapid revenue growth will aid deleveraging, high dividend payouts will weigh on credit quality

AstraZeneca's recently launched products will drive high single-digit revenue growth until 2021. However, free cash flow does not yet cover dividends payouts.

AstraZeneca PLC - June 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

AstraZeneca PLC: Update to credit analysis

Our credit view of AstraZeneca reflects credit metrics that are too weak for the A3 rating partly offset by one of the strongest pipelines in the industry.

AstraZeneca PLC - March 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Damien Conover

Morningstar | AZN Updated Forecasts and Estimates from 08 Mar 2019

AstraZeneca has built its leading presence in the pharma and biotech industry on patent-protected drugs and a developing pipeline that add up to a wide moat. The replenishment of new drugs is finally offsetting the recent patent losses on gastrointestinal drug Nexium and cholesterol reducer Crestor that have weighed on the company's growth potential. Although AstraZeneca's pipeline ranks toward the middle of its peer group, we think the company is developing several key products that hold blockbuster potential. In particular, the company's recently launched cancer drugs Tagrisso and Imfinzi ar...

Martial Descoutures ...
  • Pierre Corby

AstraZeneca : Feedback road show : Execution exceeds expectations

>Road show with CFO & Head of R&D Oncology: confidence restored - We accompanied Marc Dunoyer, CFO of Astrazeneca, and the new Head of R&D Oncology Jose Baselga (Executive VP R&D Oncology) on a road show in Paris after the publication of the FY 2018 results. It appears that, following doubts arising from recent managerial departures (drop in share price from 6,000p to 5,300p in January), the rapid reorganisation of R&D and especially the FY 2018 publication in mid-Feb...

Martial Descoutures ...
  • Pierre Corby

AstraZeneca : Feedback roadshow : une exécution qui surpasse les attentes

>Roadshow CFO & Head R&D Oncology : confiance retrouvée - Nous avons accompagné pour un roadshow parisien le CFO d’Astrazeneca Marc Dunoyer et le nouvel Head R&D Oncology Jose Baselga (Executive VP R&D Oncology) post publication des résultats FY 2018. Il en ressort que, suite à des doutes provenant des récents départs de managers (baisse du titre en janvier de 6000p à 5300p), la réorganisation rapide de la R&D et surtout la publication FY 2018 mi-février dernier, ont ...

Eric Le Berrigaud

ASTRAZENECA: A two-sided case, converging into one? | NEUTRAL | 6220p

ASTRAZENECA - NEUTRAL | 6220p(+2%) A two-sided case, converging into one? AZ is a more complex story than it looks Very high single-digit to double-digit sales growth here to last Leveraging sales growth is key We keep our NEUTRAL rating

Eric Le Berrigaud

ASTRAZENECA: A two-sided case, converging into one? | NEUTRAL | 6220p

ASTRAZENECA - NEUTRAL | 6220p(+2%) A two-sided case, converging into one? AZ is a more complex story than it looks Very high single-digit to double-digit sales growth here to last Leveraging sales growth is key We keep our NEUTRAL rating

Two Directors bought/maiden bought 2,800 shares at between 4,282p and 4,338p.

Two Directors at AstraZeneca bought/maiden bought 2,800 shares at between 4,282p and 4,338p. The significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under lis...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Martial Descoutures
  • Olfa Taamallah
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/26/2019

The acquisition of SABMiller has not delivered on its initial promises, due to the challenges of absorbing the debt quickly and a problematic geographic mix. However, the group still boasts growth potential which adjustments to its debt and asset arbitration could bring to light, particularly in the context of the shift in the ZBB (zero based budgeting) model. We simulate a partial divestment of the Asian assets and the buyout of 78% of the JVs with Castel in Africa. This would offer ...

Antoine Boivin-Champeaux ...
  • Christophe-Raphaël Ganet
  • Martial Descoutures
  • Olfa Taamallah
  • Pierre Corby

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 26/02/2019

Même si le rachat de SABMiller n’a pas répondu aux promesses initiales en raison d’un endettement difficile à résorber rapidement et d’un mix géographique contraignant, le groupe recèle encore un potentiel de croissance que le réaménagement de la dette et un arbitrage entre les actifs pourraient mettre en lumière, notamment dans le contexte de mutation du modèle ZBB (zero based budgeting). Aussi, nous simulons une cession partielle des actifs asiatiques et le rachat des 78% des JV ave...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • Jean Sassus
  • Louis Boujard
  • Martial Descoutures
  • Olivier Lebrun
  • Philippe Ourpatian
  • Pierre Corby
  • Pierre Tegner
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 02/14/2019

...

Ahmed Ben Salem ...
  • Alfred Glaser
  • Benoit Valleaux
  • Christophe-Raphaël Ganet
  • Delphine Brault
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • Jean Sassus
  • Louis Boujard
  • Martial Descoutures
  • Olivier Lebrun
  • Philippe Ourpatian
  • Pierre Corby
  • Pierre Tegner
  • Steven Gould

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 14/02/2019

...

Ahmed Ben Salem ...
  • Jean-Baptiste Rouphael
  • Jerôme Bodin
  • Johanna Jourdain
  • Martial Descoutures
  • Matthias Desmarais
  • Michael Foundoukidis
  • Pierre Corby
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Valentin Pernet
  • Veysel Taze
  • Virginie Rousseau
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 12/14/2018

...

ASTRAZENECA PLC. sees an upgrade to Positive due to a better fundamental star rating

The general evaluation of ASTRAZENECA PLC. (GB), a company active in the Pharmaceuticals industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Positive. As of the analysis date March 22, 2019, the closing price was GBp 6,351.00 and its potential was estimated at GBp 6,780.73.

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Nurhayati Wan

AstraZeneca

Tougher Sledding: Stocks Reach First Major Hurdles (GMR Weekly Notes -21 Jan 2019)

Markets This Week: Stocks: ConocoPhillips (COP); Apple (AAPL); AbbVie (ABBV); Nokia (NOK); AstraZeneca (AZN); Aurora Cannabis (ACB); General Electric (GE) Forex: EURCHF; USDRUB; AUDNZD Rates: EDZ9; 2s/10s; Bunds (GDBR10)

The 'Trap-Door'' and Other Formations; Stocks Point Lower Into Dec (GMR Weekly Notes - 26 Nov 2018)

Markets This Week: Stocks: S&P500 (SPX); DJIA (INDU); Financial Sector ETF (XLF); Goldman Sachs (GS); Dish Network (DISH); Palo Alto Networks (PANW); Microsoft (MSFT); AstraZeneca (AZN) Forex: Dollar Index (DXY); USDCNH; USDBRL Rates: 2s/5s/10s Fly (BF0205010); 5s/30s

GMR Weekly Notes - Week of 21 May 2018

Markets This Week: Stocks: Nvidia (NVDA); JD.com (JD); Charter Comm (CHTR); Facebook (FB); XLP; AstraZeneca (AZN) Rates: Gilts (GUKG10); US 10s/30s; EDZ9 FX: USDMXN; USDINT; USDZAR

MarketLine Department

F. Hoffmann-La Roche Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's F. Hoffmann-La Roche Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by F. Hoffmann-La Roche Ltd since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive a...

MarketLine Department

Summit Therapeutics Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Summit Therapeutics Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Summit Therapeutics Plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive adv...

MarketLine Department

GlaxoSmithKline Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's GlaxoSmithKline Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by GlaxoSmithKline Plc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. ...

MarketLine Department

Almirall S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Almirall S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Almirall S.A. since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key Highlig...

MarketLine Department

Novo Nordisk A/S - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments

Summary Marketline's Novo Nordisk A/S Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Novo Nordisk A/S since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. Key H...

Astrazeneca PLC – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Global Equity Strategy

Global equities (MSCI ACWI) are testing 52-week lows as prices have been consolidating over the last 1-2 months. Investors' primary sources of angst continue to revolve around concerns of (1) the global shift toward tighter monetary policy and the potential for perceived policy missteps, (2) trade and tariffs, and (3) the potential negative effects both (1) and (2) may have on global growth. Comments from Fed Chair Powell that interest rates are “just below” the neutral rate and the 90-day tariff ceasefire agreement between the U.S. and China have not been able to calm the markets. In Europe, ...

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : La tendance de fond est clairement orientée à la hausse.

La tendance de fond est clairement orientée à la hausse. Le MACD est positif, il confirme cette tendance. Le mouvement peut se poursuivre. Les objectifs suivants sont à 6 145,00 p et 6 502,00 p. La tendance serait invalidée sous le support à 5 100,00 p.

Jérôme VINERIER

Short term view - ASTRAZENECA : The background trend is clearly bullish.

The background trend is clearly bullish. The MACD is positive, it confirms that trend. The movement can go on. The following targets are at 6,145.00 p and 6,502.00 p. The trend would be invalidated below the support at 5,100.00 p.

Jérôme VINERIER

Analyse court terme - ASTRAZENECA : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 6 145,00 p. La rupture du support à 5 100,00 p invaliderait cette tendance.

Jérôme VINERIER

Short term view - ASTRAZENECA : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 6,145.00 p. Breaking below the support at 5,100.00 p would invalidate the trend.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch